Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Climb Bio Shares Jump 11% in 10 Days Since 70 Percent Antibody Reduction in Budoprutug Trial

Climb Bio Reports 70 Percent Antibody Reduction in Phase 2 Budoprutug Kidney Trial

+11.29% in 10 days $10.19 when we broke this story → $11.34 at 10:14 AM ET, 9 Nov 2026

Climb Bio announced initial Phase 2 data from its PrisMN trial evaluating budoprutug in patients with primary membranous nephropathy, showing a 70% mean reduction in PLA2R antibody levels at Week 12. These results, alongside a successful case study in minimal change disease, validate the drug's mechanism of action and support ongoing evaluation of higher dosage cohorts.

Laboratory, medical, medicine, hand. Stock photo illustrating Climb Bio's other story.
Climb Bio, Inc. · Healthcare · Photo: Belova59 / Pixabay

Key highlights

  • The 200 mg cohort achieved a 70% mean reduction in PLA2R antibody levels by Week 12
  • Five of thirteen patients or 38% in the low-dose cohort reached immunologic remission
  • Initial 600 mg cohort data showed 98% peripheral B-cell suppression at Week 4
  • A minimal change disease case study demonstrated a three-year steroid-free remission
  • Pharmacokinetic analysis revealed two-fold faster drug clearance in proteinuric patients

Initial Phase 2 Efficacy and Safety

The Phase 2 PrisMN trial evaluating budoprutug in primary membranous nephropathy demonstrated a 70% mean reduction in PLA2R antibody levels at Week 12 within the 200 mg cohort. Five out of thirteen patients achieved immunologic remission during this period. Preliminary data from the 600 mg cohort indicated deeper peripheral B-cell depletion, with 98% suppression at Week 4 compared to 74% in the lower-dose group. These findings, presented at the American Society of Nephrology Kidney Week 2026, suggest that higher dosages may offer enhanced efficacy by accounting for accelerated drug clearance observed in proteinuric patients. Most adverse events were categorized as mild to moderate, with no treatment-related serious adverse events reported.

Dose Escalation and Pharmacokinetics

A population pharmacokinetic analysis of approximately 120 subjects revealed that individuals with high proteinuria clear the antibody at least twice as fast as those without the condition. This clearance rate supports the current clinical strategy of evaluating higher dose levels to maintain therapeutic exposure. Beyond the primary trial, the company presented a case study of a patient with frequently relapsing minimal change disease (MCD) who maintained a three-year steroid-free remission after a single 100 mg dose. Consequently, enrollment has commenced for a 1000 mg cohort to further optimize the therapeutic window, with additional PrisMN trial readouts anticipated in 2027.

Strategic Clinical Outlook

“These initial PrisMN results build on our Phase 1b findings, demonstrating early immunologic activity at 200 mg and the potential for increased activity at higher doses.”

Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer, Climb Bio, Inc.

Business and Financial Context

Climb Bio is a clinical-stage biotechnology firm concentrated on developing monoclonal antibodies for immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 antibody designed to deplete B-cells responsible for autoimmune responses. The company is also advancing CLYM116 for IgA nephropathy, with Phase 2 results expected in the first half of 2027. Following a $110 million private placement and a $100 million at-the-market offering agreement earlier this year, the company reported cash and marketable securities of $239.2 million. Management anticipates this capital will fund operations into the second half of 2028, covering the completion of ongoing renal clinical programs.

Climb Bio, Inc. share price · last month
Line chart of Climb Bio, Inc.'s share price over the last month, from $9.73 on 19 Oct → $9.94 on 16 Nov; our story on 26 Oct at $10.19.

Down 2.5% since our story on 26 Oct: $10.19 when we broke it → $9.94 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$9.73
20 Oct$10.80
21 Oct$10.87
22 Oct$10.54
23 Oct$10.19
26 Oct$8.81
27 Oct$9.57
28 Oct$10.12
29 Oct$10.33
30 Oct$10.25
2 Nov$9.74
3 Nov$9.75
4 Nov$9.33
5 Nov$8.87
6 Nov$10.29
9 Nov$11.01
10 Nov$11.74
11 Nov$12.25
12 Nov$10.87
13 Nov$10.36
16 Nov$9.94
Earlier announcements by Climb Bio, Inc.
DateAnnouncementAmount
24 Oct 2026Initial Phase 2 PrisMN trial data for budoprutug in primary membranous nephropathy presented at ASN Kidney Week 2026Source: globenewswire.com–
23 Oct 2026Phase 1 healthy volunteer clinical data for CLYM116/MIL116 in IgA nephropathy presented with Mabworks at ASN Kidney Week 2026Source: ir.climbbio.com–
03 Sep 2026Positive initial Phase 1 clinical trial data and development plans announced for CLYM116 in IgA nephropathySource: globenewswire.com–
06 Aug 2026Second quarter 2026 financial results and business updates reportedSource: globenewswire.com–
12 Jun 2026Open Market Sale Agreement entered with Jefferies LLC for an at-the-market common stock offeringSource: SEC filing$100.0 Million
28 Apr 2026Securities purchase agreement entered for a private placement of common stock and pre-funded warrantsSource: SEC filing$110.0 Million

Management commentary

“These initial PrisMN results build on our Phase 1b findings, demonstrating early immunologic activity at 200 mg and the potential for increased activity at higher doses.”

Aoife Brennan, President and Chief Executive Officer

“Current treatment strategies fail to induce complete remission in most patients with pMN, underscoring the need for more effective treatments.”

Dr. Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center
Climb Bio, Inc. · financial snapshot
Share price$10.19
Market cap$585M
1-month price change-18.61%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Climb Bio, Inc. announcing initial Phase 2 clinical data for budoprutug in renal indications.

Read the filing ↗

Track Climb Bio, Inc. live

Get the next Climb Bio, Inc. SEC filing seconds after it lands.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.